Ponentes y moderadores

Josep M. Llovet, MD (Barcelona, Spain/ New York, USA)

Josep M Llovet, MD, PhD is ICREA Research Prof at IDIBAPS-Hospital Clínic and Full Prof of Medicine-Hepatic Oncology at the Univ.Barcelona. Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). He has published 371 manuscripts (citations: ~158,000 (Google scholar), h-index: 140; IF:8,590). Top 1% most cited researcher globally by Clarivate Analytics (2014-23), and world most cited investigator in liver cancer. Major achievements: a) Defining molecular and immune classes of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), b) discovery of drivers as therapeutic targets in liver cancer, and c) Establishing standard therapies for HCC, such as sorafenib, regorafenib, ramucirumab, TACE and TACE+ lenatinib/pembrolizumab, and d) Establishing mRECIST criteria for assessment of response. He is Editor-in-Chief of J HEP Reports, Founder and President of ILCA (2006-13), delivered > 750 lectures, and PI of ~110 competitive grants [coordinator, 2 EU Horizon Europe grants and 2 NIH-RO1].